Market Overview

Credit Suisse Joins Consensus To Prescribe Sarepta

Credit Suisse Joins Consensus To Prescribe Sarepta
Related SRPT
The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering
35 Stocks Moving In Thursday's Pre-Market Session
Solid Biosciences: A Classic Story Of Opportunistic Investing (Seeking Alpha)

The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold.

The Rating

Credit Suisse analysts Martin Auster, Mark Connolly and Tiago Fauth initiated coverage on Sarepta with an Outperform rating and a $178 price target.

The Thesis

Credit Suisse’s sum-of-the-parts analysis indicates significant upside opportunity for the Duchenne muscular dystrophy combatant.

“Despite high expectations for the DMD gene therapy program, we see room for continued share appreciation as the program develops,” Auster, Connolly and Fauth wrote in a note. “While we expect initial data from all three clinical stage gene therapy programs likely will demonstrate robust dystrophin expression in skeletal muscle, we think SRPT’s first mover advantage and strong initial data sets a high bar and a strong competitive position.”

The analysts expect Sarepta to release DMD gene therapy data in October, with Pfizer Inc. (NYSE: PFE) and Solid Biosciences Inc (NASDAQ: SLDB) following in 2019. The “first mover” is modeled to seize a 50-percent market share in with peak sales near $4 billion and annual recurring revenue of $1.5 billion.

Credit Suisse sees Sarepta’s DMD gene therapy representing $99 per share and PMO and PPMO candidates contributing between $35 and $60.

Price Action

Sarepta shares traded up about 1.4 percent to $142.76 at time of publication.

Related Links:

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst

Latest Ratings for SRPT

Nov 2018CitigroupMaintainsBuyBuy
Oct 2018BernsteinInitiates Coverage OnOutperform
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Credit Suisse Mark Connolly Martin Auster Tiago FauthAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga


Related Articles (PFE + SLDB)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Goldman Sachs Bearish On Standalone Rite Aid

Bank Of America Double Upgrades TCF Financial After Meeting Execs